CDE request for addition of a 9-14 years age group following 3-dose schedule as a parallel control:Licensure approval of reduced-dose schedule for HPV vaccines were granted in the EU and US on the basis of immunobridging data demonstrating non-inferiority of immune responses compared to female vaccinees in the age range where efficacy had been demonstrated following a 3-dose schedule.